![]() | |
Names | |
---|---|
Preferred IUPAC name [4-(Carbamoylamino)phenyl]arsonic acid | |
Other names (4-Ureidophenyl)arsonic acid | |
Identifiers | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.004.077 |
EC Number |
|
MeSH | Carbarson |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
| |
| |
Properties | |
C7H9AsN2O4 | |
Molar mass | 260.081 g·mol−1 |
Pharmacology | |
Oral | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Carbarsone is an organoarsenic compound used as an antiprotozoal drug for treatment of amebiasis and other infections. [1] [2] [3] It was available for amebiasis in the United States as late as 1991. Thereafter, it remained available as a turkey feed additive for increasing weight gain and controlling histomoniasis (blackhead disease). [4] [5]
Carbarsone is one of four arsenical animal drugs approved by the U.S. Food and Drug Administration for use in poultry and/or swine, along with nitarsone, arsanilic acid, and roxarsone. [6] In September 2013, the FDA announced that Zoetis and Fleming Laboratories would voluntarily withdraw current roxarsone, arsanilic acid, and carbarsone approvals, leaving only nitarsone approvals in place. [7] In 2015 FDA withdrew the approval of using nitarsone in animal feeds. The ban came into effect at the end of 2015. [8]
Anticonvulsants are a diverse group of pharmacological agents used in the treatment of epileptic seizures. Anticonvulsants are also increasingly being used in the treatment of bipolar disorder and borderline personality disorder, since many seem to act as mood stabilizers, and for the treatment of neuropathic pain. Anticonvulsants suppress the excessive rapid firing of neurons during seizures. Anticonvulsants also prevent the spread of the seizure within the brain.
Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. Several ASOs have been approved in the United States, the European Union, and elsewhere.
Meloxicam, sold under the brand name Mobic among others, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation in rheumatic diseases and osteoarthritis. It is used by mouth or by injection into a vein. It is recommended that it be used for as short a period as possible and at a low dose.
Arsanilic acid, also known as aminophenyl arsenic acid or aminophenyl arsonic acid, is an organoarsenic compound, an amino derivative of phenylarsonic acid whose amine group is in the 4-position. A crystalline powder introduced medically in the late 19th century as Atoxyl, its sodium salt was used by injection in the early 20th century as the first organic arsenical drug, but it was soon found prohibitively toxic for human use.
Sodium phenylbutyrate is a salt of an aromatic fatty acid, 4-phenylbutyrate (4-PBA) or 4-phenylbutyric acid. The compound is used to treat urea cycle disorders, because its metabolites offer an alternative pathway to the urea cycle to allow excretion of excess nitrogen. It is an orphan drug, marketed by Ucyclyd Pharma under the trade name Buphenyl, by Swedish Orphan International (Sweden) as Ammonaps, by Fyrlklövern Scandinavia as triButyrate and by Scandinavian Formulas, Inc..
Carglumic acid, sold under the brand name Carbaglu among others, is used for the treatment of hyperammonaemia.
Restylane is the trade name for a range of injectable fillers with a specific formulation of non-animal sourced hyaluronic acid (HA).
Roxarsone is an organoarsenic compound that has been used in poultry production as a feed additive to increase weight gain and improve feed efficiency, and as a coccidiostat. As of June 2011, it was approved for chicken feed in the United States, Canada, Australia, and 12 other countries. The drug was also approved in the United States and elsewhere for use in pigs.
Istradefylline, sold under the brand name Nourianz, is a medication used as an add-on treatment to levodopa/carbidopa in adults with Parkinson's disease (PD) experiencing "off" episodes. Istradefylline reduces "off" periods resulting from long-term treatment with the antiparkinson drug levodopa. An "off" episode is a time when a patient's medications are not working well, causing an increase in PD symptoms, such as tremor and difficulty walking.
Triheptanoin, sold under the brand name Dojolvi, is a medication for the treatment of children and adults with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
A feed additive is an additive of extra nutrient or drug for livestock. Such additives include vitamins, amino acids, fatty acids, minerals, pharmaceutical, fungal products and steroidal compounds. The additives might impact feed presentation, hygiene, digestibility, or effect on intestinal health.
Histomoniasis is a commercially significant disease of poultry, particularly of chickens and turkeys, due to parasitic infection of a protozoan, Histomonas meleagridis. The protozoan is transmitted to the bird by the nematode parasite Heterakis gallinarum. H. meleagridis resides within the eggs of H. gallinarum, so birds ingest the parasites along with contaminated soil or food. Earthworms can also act as a paratenic host.
Selenium yeast is a feed additive for livestock, used to increase the selenium content in their fodder. It is currently an approved form of selenium for human consumption in the EU and Britain. Inorganic forms of selenium are used in feeds, sodium selenate and sodium selenite, which appear to work in roughly the same manner, but this is a product that can be patented, which means producers can demand premium prices. It is produced by fermenting Saccharomyces cerevisiae in a selenium-rich media.
Baricitinib, sold under the brand name Olumiant among others, is a medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.
Nitarsone is an organoarsenic compound that is used in poultry production as a feed additive to increase weight gain, improve feed efficiency, and prevent histomoniasis. It is marketed as Histostat by Zoetis.
Tenapanor, used in form of tenapanor hydrochloride and sold under the brand name Ibsrela, is a treatment for adults with a disease of the gut called irritable bowel syndrome with constipation commonly referred to as IBS-C.
Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. The FDA's "breakthrough therapy" designation is not intended to imply that a drug is actually a "breakthrough" or that there is high-quality evidence of treatment efficacy for a particular condition; rather, it allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases. The FDA has other mechanisms for expediting the review and approval process for promising drugs, including fast track designation, accelerated approval, and priority review.
Arsonic acids are a subset of organoarsenic compounds defined as oxyacids where a pentavalent arsenic atom is bonded to two hydroxyl groups, a third oxygen atom, and an organic substituent. The salts/conjugate bases of arsonic acids are called arsonates. Like all arsenic-containing compounds, arsonic acids are toxic and carcinogenic to humans.
Bempedoic acid, sold under the brand name Nexletol among others, is a medication for the treatment of hypercholesterolemia.
Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol. It is a combination of bempedoic acid and ezetimibe.